Brno, August 29, 2022 – After working for CasInvent since March as their R&D consultant, Alexander Scheer will now assume full responsibility for R&D activities of CasInvent Pharma, a.s. at the position of CSO.
CasInvent Pharma, a.s., an early-stage drug discovery company developing a proprietary small-molecule lead compound with anticancer properties, announced that the company has appointed Alexander Scheer as Chief Scientific Officer. Together with Vojtech Helikar, Chief Executive Officer and the chairman of the board of directors of Casinvent, Alexander will complete the newly formed board of directors. Alexander Scheer has more than 25 years of experience in R&D and the life science industry. Prior to joining CasInvent, he served as the CSO of Aelin Therapeutics in Belgium and before as CSO for Erytech in Lyon, France. Prior to that he was the Head of Research at Pierre Fabre in France, focused primarily on oncology and central nervous system research. Before his time in France, he worked at different positions with increasing responsibilities for Merk and Serono in Geneva, Switzerland. He earned his MSc at the University of Göttingen in organic chemistry, followed by a PhD at the German Cancer Research Center in Heidelberg, Germany.
Vojtech Helikar, CEO of CasInvent, said: “We are delighted to appoint Alexander as our CSO and complete our new management team. Alexander has more than 20 years of experience in drug discovery, spanning the preclinical and translational activities in oncology. Alexander has been a key partner to our company for the last several months, and with his experience, he is perfectly placed to build on the outstanding progress of CasInvent and maximize the value of our pipeline.”
© 2022 Casinvent